21. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (CONTINUED) Liquidity risk The Group’s financial liabilities, comprising trade and other payables and derivatives, are generally repayable within 1 – 3 months. The maturity and availability of financial assets, comprising cash and cash equivalents, short-term investments and trade and other receivables, are monitored and managed to ensure financial liabilities can be repaid when due. Capital management The Group monitors capital including share capital, retained earnings and reserves and the cash and cash equivalents and short-term investments presented in the consolidated statement of financial position. The Group has no debt. The key objective of the Group when managing its capital is to safeguard its ability to continue as a going concern, so that the Group can sustain the future development of the research and development activities being performed by the Group. 22. KEY MANAGEMENT PERSONNEL DISCLOSURES The Key Management Personnel of the Group (KMP) include the directors of the Company and employees who report directly to the Managing Director. Compensation for KMP was as follows: Year ended Dec 2025 $’000 Year ended Dec 2024 $’000 Short-term employee benefits 2,141 1,864 Post-employment benefits 172 158 Long-term benefits 94 37 Share-based payments 1,423 98 3,830 2,157 23. RELATED PARTY TRANSACTIONS Parent entity Neuren Pharmaceuticals Limited is the ultimate parent entity (“Parent”). Subsidiaries Interests in subsidiaries are set out in Note 19. The Parent funds the activities of the subsidiaries throughout the year as needed. All amounts due between entities are payable on demand and bear no interest. Key management personnel Disclosures relating to key management personnel are set out in Note 22. Transactions with related parties There were no transactions with related parties during the current and previous financial year. Receivable from and payable to related parties There were no trade receivables from or trade payables to related parties at the current and previous reporting date. Loans to/from related parties There were no loans to or from related parties at the current and previous reporting date. 24. EVENTS AFTER THE REPORTING PERIOD Subsequent to year end, Neuren Pharmaceuticals Limited announced its intention to commence an on‑market share buy‑back program. The program will permit the Company to repurchase up to 5% of the total shares on issue, as at 12 months prior to the commencement of the buy‑back. The buy‑back may be undertaken at the Company’s discretion over a period of up to 12 months. No other matter or circumstance has arisen since 31 December 2025 that has significantly affected, or may significantly affect the consolidated entity’s operations, the results of those operations, or the consolidated entity’s state of affairs in future financial years. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS CONTINUED Neuren Pharmaceuticals Limited Annual Report 2025 55
RkJQdWJsaXNoZXIy MjE2NDg3